A Takeda quality executive demonstrates how a team of AI agents uses synthetic data to provide decision support ahead of CDMO audits.
- Early CDMO Engagement For Cell Therapies? CellProthera's CEO Thinks Not
- Closing The MES Value Gap: Why Technology Isn't The Problem
- Prevascularized Bio-hybrid Organ Platforms Are Redefining Cell Therapy Delivery
- Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook
- Can A Biotech Create A CDMO Market?
- Why Are Life Science Companies So Poorly Prepared For RIM's Future?
- April 2026 — CDMO Opportunities And Threats Report
- Cell And Gene Therapies: The Emerging Reality For Scalable Market Readiness
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
How We Used Intelligent Automation to Transform Vendor Selection
Discover how your small biotech can achieve faster timelines, improved cost control, and more strategic, transparent choices with a platform leveraging intelligent automation.
-
Mid-Sized Pharma Optimizes Local Affiliate Safety Operations
Managing local affiliate PV strains any team. See how a mid-sized biopharma standardized ICSR processing across 94 countries, improved compliance tracking, and achieved centralized oversight.
-
Rapid And Sensitive Detection Of Replication-Competent Lentivirus (RCL)
See how a rapid digital PCR workflow enables reliable detection of trace RCL levels while maintaining strong performance in complex samples, which support more confident decisions in manufacturing.
-
Automated DNA Size Selection For Flexible NGS Workflow Integration
Gain insight into automating DNA size selection that shows how optimized bead ratios and programmable handling improve fragment recovery, consistency, and throughput.
-
The Complete Guide To Immunohistochemistry
Immunohistochemistry (IHC) is a tool for visualizing the distribution and localization of antigens within tissue sections. Learn about IHC sample preparation, detection and amplification systems, and more.
-
Advancing Genomic Discoveries With Comprehensive Sequencing Support
See how a leading genomics facility advances long‑read sequencing through rigorous QC and flexible workflows, offering practical insights for researchers aiming to improve sequencing outcomes.
-
Enhancing Safety And Efficacy Of mRNA-Based Therapeutics
Discover how Codex® HiCap RNA Polymerase optimizes mRNA yield while reducing dsRNA byproducts for safer, more effective therapeutics.
-
Smart Scale-Up: Expanding Viral Vectors With Microcarrier Bead Technology
Scale up your manufacturing of adherent cell cultures used for viral vector-based treatments with the novel technologies needed to facilitate safe, rapid production.
-
Advanced Sequencing Approaches For Comprehensive AAV Vector Characterization
Short and long read sequencing offer complementary insights into AAV vector identity, integrity, and impurity profiles, helping developers improve safety, efficacy, and scalability of gene therapy products.
-
A Transient Cell Line To Produce rAAV With Low-Level hcDNA Encapsidation
Discover the ability of a novel HEK293 suspension cell line for efficient and scalable rAAV production across various serotypes with low encapsidated host cell DNA levels.
NEWSLETTER ARCHIVE
- 05.18.26 -- Strengthen Your Data Integrity and Safety
- 05.18.26 -- FDA's First cGMP Enforcement Action On AI Misuse In Drug Manufacturing
- 05.15.26 -- Sana, Mayo Clinic Advance A New Model For Cell Therapy Delivery In T1D
- 05.14.26 -- Discover critical components for fluid management and flow control
- 05.14.26 -- Early CDMO Engagement For Cell Therapies? CellProthera's CEO Thinks Not
- Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook
- Regeneron Advances In Vivo Gene Therapy For Hearing Loss
- Sana, Mayo Clinic Advance A New Model For Cell Therapy Delivery In T1D
- Reprogramming T-Cell Access To Solid Tumors Through Improved Trafficking And Entry
- Target Selection Drives The Future Of CAR T Therapy In Solid Tumors
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections